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Abstract At the moment, there is no clear molec-
ular explanation for the steeper decline in muscle
performance after menopause or the mechanisms of
counteractive treatments. The goal of this genome-wide
study was to identify the genes and gene clusters
through which power training (PT) comprising
jumping activities or estrogen containing hormone
replacement therapy (HRT) may affect skeletal
muscle properties after menopause. We used musculus
vastus lateralis samples fromearly stagepostmenopausal
(50–57 years old) women participating in a yearlong
randomized double-blind placebo-controlled trial with
PT and HRT interventions. Using microarray platform
with over 24,000 probes, we identified 665 differentially
expressedgenes.Thehierarchicalclusteringmethodwas
used to assort the genes. Additionally, enrichment
analysis of gene ontology (GO) terms and Kyoto
EncyclopediaofGenesandGenomes(KEGG)pathways
was carried out to clarify whether assorted gene clusters
are enriched with particular functional categories. The
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Helsinki, Finlandanalysis revealed transcriptional regulation of 49 GO/
KEGG categories. PT upregulated transcription in
“response to contraction”—category revealing novel
candidate genes for contraction-related regulation of
muscle functionwhile HRTupregulatedgeneexpression
related to functionality of mitochondria. Moreover,
several functional categories tightly related to muscle
energy metabolism, development, and function were
affected regardless of the treatment. Our results empha-
size that during the early stages of the postmenopause,
muscle properties are under transcriptional modulation,
which both PT and HRT partially counteract leading to
preservation of muscle power and potentially reducing
the risk for aging-related muscle weakness. More
specifically, PT and HRT may function through
improving energy metabolism, response to contrac-
tion as well as by preserving functionality of the
mitochondria.
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Introduction
Menopause, the transition from the reproductive to
non-reproductive stage, is a complex physiological
process, often accompanied by additional effects of
aging (Nelson 2008). In addition to reproductive
viability, deterioration in musculoskeletal properties
begins to accumulate (Kallman et al. 1990; Phillips et
al. 1993; Samson et al. 2000), which may lead to
severe consequences for the quality of life and the
ability to recover from physical traumas ultimately
reducing the healthspan of women. Therefore, early
preventative actions to maintain adequate muscle
performance in later life are needed.
So far the best prevention strategy against aging-
related weakness is physical exercise (Greenlund and
Nair 2003; Taaffe 2006). Strength, endurance, and
power training have been found to exhibit beneficial
albeit differential effects on aging musculature (e.g.,
Hoppeler et al. 1985; Häkkinen et al. 2000; Roth et al.
2001; Timmons et al. 2005; Porter 2006; Hazell et al.
2007; Henwood et al. 2008; Orsatti et al. 2008).
Progressive power training such as undertaken in the
current study, is associated with enhanced quality of
life, i.e., physical functioning and well-being (Katula
et al. 2008), neuromuscular functions involving rapid
force production (Sipilä et al. 2001; Taaffe et al.
2005), and bone formation (Cheng et al. 2002).
Moreover, muscle power is essential for many daily
tasks such as climbing stairs, rising from chair, and
preventing a fall after a slip leading a number of
recent studies (Hazell et al. 2007; Paterson et al. 2007;
Katula et al. 2008; Orr et al. 2008) to conclude that
strategies improving muscle power and composition
are essential in order to prevent old age disability.
Therefore, power training is promising training mode
for postmenopausal women whose risk for osteopo-
rosis and neuromuscular dysfunction might otherwise
be increased. However, the genome-wide effects of
this specific type of training on skeletal muscle have
not, until now, been investigated.
In addition to physical exercise, the restoration of
female sex hormones to near pre-menopausal levels
may represent one way to attenuate functional decline
and muscle loss after menopause. Indeed, several
randomized controlled trials (RCT) have shown that
hormone replacement therapy (HRT) increases muscle
mass and improves neuromuscular performance when
used in the beginning of the postmenopausal period
(Skelton et al. 1999; Sipilä et al. 2001; Dobs et al.
2002; Taaffe et al. 2005). In addition, a co-twin study,
in which monozygotic HRT users were compared to
their non-using sisters, showed that long-term HRT
treatment is associated with greater muscle power,
higher walking speed, and decreased total body and
thigh fat content (Ronkainen et al. 2009). However,
not all trials with HRT have reported beneficial effects
on muscle and physical function (Ribom et al. 2002;
Tanko et al. 2002; Kenny et al. 2005) indicating the
need for additional research to clarify this discrepancy.
In our yearlong RCT, the exercise and hormone
replacement therapy-study (Ex/HRT), the effects of
plyometric power training and HRT on bone as well
as muscle structure and function in postmenopausal
women were studied (Sipilä et al. 2001; Cheng et al.
2002; Taaffe et al. 2005). We found a significant 6%
increase in muscle power with power training and 7%
with HRT, while a 5% reduction was observed in
control participants without any treatments (Sipilä et
al. 2001). Running speed increased by 4% both after
HRT and power training and reduced by 2% in the
controls (Taaffe et al. 2005). Moreover, knee extensor
muscle density increased significantly by both power
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beneficial changes in muscle composition in favor of
muscle tissue itself on the expense of adipose tissue
(Goodpaster et al. 2000). Knee extensor muscle cross-
sectional area increased by 6% with HRT (Sipilä et al.
2001). Our earlier microarray study investigating the
effects of 1-year HRT use showed that the postmen-
opausal women without treatment have notable
changes in their muscle transcriptome and that these
changes were largely counteracted by the use of HRT
(Pöllänen et al. 2007). To the best of our knowledge,
other microarray studies on the effects of HRT or
power training on skeletal muscle of postmenopausal
women have not previously been undertaken.
The purpose of this ancillary genome-wide analy-
sis of the Ex/HRT study was to identify gene clusters
that are affected by progressive power training, use of
HRT or recent menopause, and thus may induce the
adaptive changes in skeletal muscle characteristics. To
accomplish our goal, we combined previously
obtained microarray data with completely new data
from eight power trainers and four control women
(totally ten HRT users, eight trainers, and nine non-
treated women). This allowed us to identify both
unique and overlapping effects of the two treatments
on muscle transcriptome.
Materials and methods
Study design and interventions
The detailed description of the study design has been
reported by Sipilä et al. 2001. The trial is registered in
the Current Controlled Trials with ISCTN number
ISRCTN49902272 (http://www.controlled-trials.com/
ISRCTN49902272). Briefly, we enrolled 1,333 women
at age 50–57 years living in the area of the municipality
of Jyväskylä in Finland. From these women, 118 went
through an extensive medical and physical examination
including determination of their menopausal status as
wellaseligibilitytothe study.Tobeeligiblefor the trial,
participants had to have no serious medical conditions;
no current or previous use of medication including
estrogen, fluoride, calcitonin, biophosphonates, or ste-
roids; last menstruation at least 0.5 years but not more
than 5 years ago; FSH level above 30 IU/L; and no
contraindications for exercise and HRT. Finally, we
randomly assigned 80 women fulfilling the inclusion
criteria, i.e., being at the very early stage following
menopause, to one of four study groups: power training
(PT, n=20), HRT (n=20), PT+HRT (n=20), and
control (CO, n=20).
For the current microarray analysis, baseline and
12-month muscle samples were available from eight
PT, ten HRT, and nine CO women. Seventeen
participants were lost during the intervention, and
muscle samples from both baseline and post-
intervention (12-months) were not available from 14
subjects. Moreover, one participant did not consent
for the microarray study. The analysis does not
include the PT+HRT group due to the small number
of tissue samples available (n=6). The participants
available for the microarray study did not differ
significantly from the whole study sample in any of
the tested muscle phenotype variables at baseline or in
changes during the intervention.
Muscle biopsies obtained from the mid-part of
musculus vastus lateralis (midpoint between the
greater trochanter and the lateral joint line of the
knee) were taken at baseline and after completion of
the study as previously described (Pöllänen et al.
2007). The biopsy protocol was standardized within
the study in order to avoid sampling-induced varia-
tion. All muscle biopsies were taken from the side of
the dominant hand approximately at the same time of
day by the same experienced physician. The 12-month
biopsy was taken 1 cm above the previous biopsy
cicatrix within 3 to 5 days after completion of the
intervention. The histological evaluation of the samples
did not reveal any signs of damage, such as central
nuclei, in any of the samples.
The detailed description of the interventions is
reported in Sipilä et al. 2001. In brief, PT participants
underwent a progressive plyometric training program
for the lower limbs, which comprised two supervised
sessions per week and four home-based unsupervised
sessions per week. The training was performed in a
circuit format including bounding, drop jumping,
hopping, and skipping performed at high velocity in
order to improve muscle power production and to
produce high-impact loading for bones. The training
program progressed in the number of rotations
performed, volume of work undertaken as well as
height of obstacles for bounding and height for drop
jumping. Each supervised session included three to
four resistance training exercises for the upper body
and commenced with a warm-up period and conclud-
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HRT and CO subjects were advised to maintain their
daily routines without altering their physical activity
patterns. The HRT treatment was conducted double-
blind. All study participants used either continuous,
combined HRT preparation containing estradiol (2 mg)
and or noretisterone acetate (1 mg) preparation (Klio-
gest, Novo Nordisk, Copenhagen, Denmark) or placebo
(composed of lactose monohydrate, cornstarch, gelatin,
talc, and magnesium stearate, which were auxiliary
substances in the Kliogest tablet) one tablet every day.
The study was carried out in accordance with the
Declaration of Helsinki (48th WMA General assembly;
1996 1989) of the World Medical Association (www.
wma.net) and was approved by the ethics committee of
the Central Finland Health Care District. Informed
consent was given by all subjects.
RNA preparation, cRNA generation, and array
hybridization
The RNA preparation, cRNA generation, and array
hybridization procedures have been previously
described (Pöllänen et al. 2007). Briefly, Trizol-
reagent (Invitrogen, Carlsbad, CA, USA) was used
to isolate RNA from biopsy samples homogenized on
FastPrep FP120 apparatus (MP Biomedicals, Illkrich,
France). The Experion (Bio-Rad Laboratories, Hercu-
les, CA, USA) was used to inspect RNA concentra-
tion and quality. Only pure, good-quality RNA was
used in further analysis (260/280 ratio >1.8). An
Illumina RNA amplification kit (Ambion, Austin, TX,
USA) was used according to the manufacturer's
instructions to obtain biotin-labeled cRNA from
500 ng of total RNA. Experion was used to perform
quality control after amplification. Hybridization to
the HumanRef-8 v1.0 or HumanWG-6 v1.0 Bead-
Chips (Illumina Inc., San Diego, CA) as well as
washing and scanning was performed according to the
Illumina BeadStation 500x manual (revision C). Both
samples (baseline and follow-up) from each study
subject were always hybridized onto the same chip.
The slides were scanned by confocal laser scanning
system (Illumina BeadReader Rev. C, Illumina Inc.,
San Diego, CA, USA). The data were acquired by the
BeadStudio Direct Hybridization V.1.5.0.34. The
Turku Centre for Biotechnology (Turku, Finland)
carried out the cRNA generation, array hybridiza-
tions, and quality control of the raw data. The data
discussed in this publication have been deposited in
NCBI's Gene Expression Omnibus (GEO; Edgar et al.
2002) and are accessible through GEO Series acces-
sion number GSE16907 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE16907). The MIAME
guidelines were followed during array data genera-
tion, preprocessing, and analysis.
Array data preprocessing and validation
Raw gene expression data from eight PT and four CO
participants were obtained by using Human WG-6
BeadChips (Illumina), while HumanRef-8 BeadChips
(Illumina) were utilized for ten HRT and five CO
participants. Raw data from both BeadChips were
combined, and only the probes, which are identical in
both platforms, were included in further analysis.
Consequently, over 24,000 probes for approximately
21,000 NCBI RefSeq-transcripts were included. Signal
for each transcript comes from approximately 30
independent technical replicates (beads) as described
previously (Pöllänen et al. 2007). Quality control and
visualization of the raw, combined expression data
were performed with aid of box plots, hierarchical
clustering, correlation matrix, and principal component
analysis. Microarray data from the three study groups,
i.e., PT, HRT, and CO, were normalized separately
using the quantile normalization method implemented
in the Affy-package (Gautier et al. 2004)o ft h eR /
Bioconductor analysis software (www.r-project.org,
www.bioconductor.org). Samples (n=6) from three
CO subjects were hybridized onto both Illumina
platforms in order to compare the performance of
previous and current arrays with the Pearson correla-
tion coefficient test. Even though the correlation of the
data produced by the same samples on different
Illumina platforms was high (r=0.88–0.94), the clear
batch effect caused by two different platforms was
visible. This was corrected in statistical analyses by
using array type as a covariate.
Data analysis
After preprocessing the microarray data, the Limma
package (Smyth 2004) of R was used to identify
differentially expressed genes within each condition.
The fold changes (FC) and p values calculated by
Limma methods were used as filtering criteria in order
to detect genes up- or downregulated within each
350 AGE (2010) 32:347–363study group. The repeated measurements design and
the batch effect caused by the usage of two different
array types were taken into account in statistical
testing. At this point, we chose to use quite low
stringency thresholds (p value <0.05 and |FC| >1.2) in
order to list a reasonable number of the genes most
likely to be differentially expressed. Decreasing or
increasing the thresholds resulted in poorer cluster
structures in the clustering of the filtered genes. Genes
determined to be differentially expressed within at
least one of the study groups were used in further
analyses, which allow identifying co-regulated gene
clusters, i.e., genes, which show consistent behavior
being either up- or downregulated within each study
group.We applied hierarchicalclusteringwithPearson's
metrics to form clusters of most similarly behaving
genes. The Pearson's correlation thresholds were set to
0.95. Additionally, extensive analysis of functional
categories, i.e., gene ontology (GO) terms (Ashburner
et al. 2000) and Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways (Kanehisa et al. 2006),
was carried out to clarify whether certain gene clusters
are enriched with particular functional categories.
Hypergeometric test and false positive discovery rate
calculation were applied to identify the most significant
categories. GenoSyst Ltd carried out the hierarchical
clustering with enrichment analysis. The results
obtained were further analyzed and processed in
our lab. PatternViewer 2.39 (GenoSyst Ltd, Turku,
Finland) was used to visualize the results.
Results
Co-regulated gene clusters
Differentially expressed genes were defined as genes
that differed between follow-up and baseline samples
within a study group with statistical threshold p value
<0.05 and |FC| >1.2. These thresholds led to the
discovery of 665 genes. In the PT group, 328 genes
were upregulated and 182 downregulated, whereas in
the HRT group, 34 genes were upregulated and 20
downregulated. The corresponding numbers for the CO
group were 91 and 70, respectively. A non-redundant
list of differentially expressed genes was used in the
analysis of co-regulated gene clusters. Genes were
sorted into eight significant and consistent clusters
(Fig. 1,T a b l e1), which showed either study group-
specific regulation or regulation into the same direction
within all study groups. As seen in Fig. 1, genes within
each cluster had a highly consistent expression pattern
forming congruent cluster structure. The complete list
of genes belonging to each cluster is presented in Table
S1 as supporting information. For clarity, the official or
commonly used acronym for gene names are used in
the text and complete gene names with proper
annotation are provided as supporting information in
Table S2.
Enrichment analysis
The identified gene clusters (CL #1–8) were diligently
investigated in order to clarify whether they were
enriched with particular GO terms or KEGG path-
ways. The algorithms used in the analysis allow
determination of the percentage of false positive
discovery (FP-%), which enables monitoring the
expected proportion of false positives among the
discovered patterns. The FP-% is obtained by com-
paring the permutated (at least 1,000 simulations)
cluster-annotation pairs to the actually observed
cluster-annotation pairs, and it allows efficient and
visual selection of the significant cut-offs with an
acceptable level of false discovery (Fig. 2). Due to the
hypothesis-generating rather than hypothesis-proofing
nature of the microarray studies, we selected FP-%
<15%. For the GO terms, a p value <0.0005 was used
as the cut-off value. With this cut-off, there are 26
significantly enriched GO terms from which theoret-
ically three might be false positives (FP-% ∼12%).
For the KEGG pathways, a p value <0.005 is
sufficient to tolerate similar proportion of false
positives (FP-% ∼10%). This cut-off value identifies
23 significant KEGG pathways. The results of the
enrichment analyses are presented in Tables 2 and 3
and thoroughly examined below with a summary of
the main results presented in Fig. 3.
Power training-specific functional categories
The PT-specific gene clusters were CL #2 and CL #8,
which consisted of 82 upregulated and 20 down-
regulated genes, respectively (Fig. 1b, h, Table 1). CL
#2, which was specifically upregulated in the PT
group and downregulated in the HRT and CO groups
(Fig. 1b), including 13 genes without GO or KEGG
annotations, 29 genes with annotation “cytoplasm,”
AGE (2010) 32:347–363 351and 9 genes with annotation “actin binding” (Table 2).
GO term “cytoplasm” constitutes 42% of the whole
cluster and refers to all cellular actions taking place
within the cytoplasmic entity of cells excluding the
cell membrane and the nucleus. One of the most
highly upregulated genes in CL #2 was the STARS
gene, which belongs to both “cytoplasm” and “actin
binding” GO terms. STARS expression was 50%
upregulated among the PT women, whereas the
expression was 16% downregulated within the HRT
Fig. 1 Graphical view of the cluster structure within each cluster (CL #1–CL #8). Each line represents the mean fold change (FC) of a
single gene
352 AGE (2010) 32:347–363and 46% downregulated within the CO group
(Supporting Table S1). In addition, five genes encod-
ing kinases, five encoding proteins related to apopto-
sis or proteolysis, four encoding signal transducers,
four encoding proteins involved in regulation of
transcription, and three encoding structural proteins
were included in “cytoplasm” and/or “actin binding”
GO terms. Moreover, CL #2 was significantly
enriched with “insulin” and “adipocytokine signaling”
KEGG pathways (Table 3). The genes contributing
most to the significance of these upregulated path-
ways in the PT group were MKNK2, GLUT4, FASN,
AKT2, PRKAR2A,a n dSTK11. The enrichment
analysis did not reveal any statistically significant
functional categories from CL #8. This is probably
due to the fact that 40% of the genes in this cluster
were unclassified having neither GO nor KEGG
annotation.
HRT-specific functional categories
The HRT-specific gene clusters were CL #5, which
consisted of 45 upregulated genes, and CL #7, which
included 31 downregulated genes (Fig. 1e, g, Table 1).
Eleven genes did not have GO or KEGG annotation.
According to enrichment analysis (Table 2), the use of
HRT significantly upregulated transcription related to
GO term “mitochondrion” and downregulated tran-
scription of genes involved in “regulation of cell
growth”. We did not find any significant HRT-specific
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Table 1 Differentially expressed genes formed eight distinctive clusters
Clusters Classification of the clusters Number of genes
in cluster
Number of genes with
GO annotation
Number of genes with
KEGG annotation
Number of
unclassified genes
CL #1 Uniform upregulation 224 199 61 23
CL #2 PT-specific upregulation 82 69 20 13
CL #3 Uniform downregulation 139 119 46 20
CL #4 Upregulation in the PT and
HRT groups
81 71 22 9
CL #5 HRT-specific upregulation 45 41 21 4
CL #6 Downregulation in the PT
and HRT groups
43 19 3 24
CL #7 HRT-specific downregulation 31 24 12 7
CL #8 PT-specific downregulation 20 12 5 8
AGE (2010) 32:347–363 353enrichment of KEGG-annotated pathways. Genes
from “mitochondrion” included four genes encoding
mitochondrial ribosomal proteins (MRPS12, MRPS36,
MRPL27,a n dMRPL33), one encoding mitochondrial
chaperon (HSPE1), four genes directly involved with
energy metabolism through oxidative phosphorylation
(ATP5H and COX7A2), citric acid cycle (IDH3A)o r
fatty acid oxidation (PECI), and three genes involved
with other mitochondrial functions (MTP18,
PTPMT1,a n dTST). CL #7 had one significant
category, the “regulation of cell growth”,w h i c h
included three genes (ING1L, CHAD, and UBE2E3).
Functional categories affected by both PT and HRT
Both interventions, that is, one year of either PT or
HRT, resulted in parallel upregulation of 81 genes
(CL #4) and downregulation of 43 genes (CL #6) in
contrast to that observed in the CO group (Fig. 1d, f,
Table 1). Nine KEGG pathways were significantly
Table 2 Enrichment of GO terms into the co-regulated gene clusters. Note, numbers of genes are presented as they occur in the GO terms,
meaning that they may be included in several different terms. Corrected p value is obtained by multiplying by the number of hypothesis tested
GO ID Term description Number of genes
in cluster/array
p value Corrected
p value
CL #1: uniform upregulation, 199 GO-annotated genes
GO:0006936 Muscle contraction 7/84 3.29E−5 0.019
GO:0006941 Striated muscle contraction 5/36 3.86E−5 0.023
GO:0005977 Glycogen metabolic process 4/21 6.63E−5 0.039
GO:0007517 Muscle development 6/85 3.04E−4 0.179
GO:0007519 Skeletal muscle development 4/31 3.21E−4 0.189
GO:0004368 Glycerol-3-phosphate dehydrogenase activity 2/3 3.40E−4 0.201
GO:0030731 Guanidinoacetate N-methyltransferase activity 2/3 3.40E−4 0.201
GO:0016600 Flotillin complex 2/3 3.40E−4 0.201
CL #2: PT specific upregulation, 69 GO-annotated genes
GO:0003779 Actin binding 9/329 3.42E−6 0.001
GO:0005737 Cytoplasm 29/4142 1.91E−4 0.050
CL #3: uniform downregulation, 119 GO-annotated genes
GO:0047115 Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity 3/4 1.02E−6 0.001
GO:0004033 Aldo-keto reductase activity 3/10 2.98E−5 0.013
GO:0047026 3-Alpha-hydroxysteroid dehydrogenase A-specific activity 2/2 4.07E−5 0.018
GO:0047042 3-Alpha-hydroxysteroid dehydrogenase B-specific activity 2/2 4.07E−5 0.018
GO:0006937 Regulation of muscle contraction 3/12 5.41E−5 0.024
GO:0005739 Mitochondrion 17/944 1.07E−4 0.048
GO:0045737 Positive regulation of cyclin-dependent protein kinase activity 2/3 1.22E−4 0.054
GO:0048306 Calcium-dependent protein binding 3/17 1.63E−4 0.073
O:0032052 Bile acid binding 2/4 2.42E−4 0.108
GO:0015721 Bile acid and bile salt transport 2/4 2.42E−4 0.108
GO:0001527 Microfibril 2/4 2.42E−4 0.108
GO:0016491 Oxidoreductase activity 11/481 2.67E−4 0.119
GO:0005578 Proteinaceous extracellular matrix 8/265 3.09E−4 0.138
GO:0031072 Heat shock protein binding 4/57 4.87E−4 0.217
CL #5: HRT-specific upregulation, 41 GO-annotated genes
GO:0005739 Mitochondrion 12/944 5.56E−7 0.001
CL #7: HRT-specific downregulation, 24 GO-annotated genes
GO:0001558 Regulation of cell growth 3/114 4.15E−4 0.052
354 AGE (2010) 32:347–363enriched among the upregulated genes (Table 3).
These pathways included signaling related to carbo-
hydrate metabolism (KEGG pathways 00710, 00010,
and 04190 in Table 3) and calcium signaling (KEGG
pathways 04020, 04720, 04912, 04916, 05040, and
05214 in Table 3). One of the most dramatically
affected genes was ALDOAwith expression over 70%
upregulated in the PT, 20% upregulated in the HRT,
and 10% downregulated in the CO group (Supporting
Table S1). This enzyme catalyzes conversion of C6-
carbohydrates to C3-carbohydrates being the initial
step in the energy producing instead of energy
consuming phase of glycolysis. Other upregulated
genes contributing to carbohydrate metabolism
through “glycolysis/glyconeogenesis” or “insulin sig-
naling” were PKM2, which catalyzes the last step of
glycolysis, TPI1, PHKG1, FOXO1A, MKNK2,
CALM1, and CALM3. According to KEGG annota-
tions CALM1, CALM3, and PHKG1 are also involved
in the “calcium signaling pathway”. In addition,
DCTN1, CaMK2A, CaMK2B, FZD7,a n dDVL1
genes, which encode proteins also involved in
“calcium signaling”, were upregulated in the PT and
HRT women.
Table 3 Enrichment of KEGG pathways into the co-regulated gene clusters. Note, the number of genes is presented as they occur in
the KEGG pathways, meaning that they may be included in several different pathways. Corrected p value is obtained by multiplying
by the number of hypothesis tested
KEGG ID Term name Number of genes in
cluster/array
p value Corrected p value
CL #1: uniform upregulation, 61 KEGG-annotated genes
04910 Insulin signaling pathway 9/163 1.06E−4 0.010
00010 Glycolysis/gluconeogenesis 6/78 2.81E−4 0.026
00030 Pentose phosphate pathway 4/29 3.36E−4 0.031
05120 Epithelial cell signaling in Helicobacter pylori infection 5/79 2.25E−3 0.205
04370 VEGF signaling pathway 5/91 4.17E−3 0.379
CL #2: PT specific upregulation, 20 KEGG-annotated genes
04910 Insulin signaling pathway 5/163 3.11E−4 0.015
04920 Adipocytokine signaling pathway 3/83 3.75E−3 0.184
CL #3: uniform downregulation, 46 KEGG-annotated genes
00980 Metabolism of xenobiotics by cytochrome P450 7/65 1.31E−6 9.83E−5
00190 Oxidative phosphorylation 6/114 4.62E−4 0.035
05216 Thyroid cancer 3/37 4.16E−3 0.312
05010 Alzheimer's disease 3/38 4.49E−3 0.337
03320 PPAR signaling pathway 4/77 4.64E−3 0.348
00072 Synthesis and degradation of ketone bodies 2/12 4.84E−3 0.363
CL #4: upregulation in the PT and HRT, 22 KEGG-annotated genes
00710 Carbon fixation 3/29 2.28E−4 0.008
04720 Long-term potentiation 4/85 3.99E−4 0.015
05214 Glioma 4/88 4.56E−4 0.017
05040 Huntington's disease 3/48 1.03E−3 0.038
04020 Calcium signaling pathway 5/212 1.65E−3 0.061
04912 GnRH signaling pathway 4/132 2.09E−3 0.077
00010 Glycolysis/gluconeogenesis 3/78 4.15E−3 0.154
04916 Melanogenesis 6/127 1.06E−5 3.93E−4
04910 Insulin signaling pathway 6/163 4.43E−5 0.002
CL #6: downregulation in the PT and HRT, 3 KEGG annotated genes
04360 Axon guidance 2/174 3.31E−3 0.007
Table 3 Enrichment of KEGG pathways into the co-
regulated gene clusters. Note, the number of genes is
presented as they occur in the KEGG pathways, meaning
that they may be included in several different pathways.
Corrected p value is obtained by multiplying by the number of
hypothesis tested
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pathway among both PT and HRT women was “axon
guidance” (Table 3), including two moderators of G-
protein signaling, the RGS3 and SRGAP2. Only three
of the 43 genes belonging to CL #6 had KEGG
annotation and 19 out of 43 had GO annotation,
leaving 24 genes of CL #6 without any annotations at
all.
Functional categories, which were changed into same
direction in all study groups
The largest and most heterogeneous clusters were
CL #1 with 224 genes and CL #3 with 139 genes
(Fig. 1a, c,T a b l e1). Transcription of genes in these
clusters was either upregulated or downregulated
within all three study groups, i.e., neither PT nor
HRT was able to reverse the regulation of these
genes. CL #1 with uniform upregulation is mainly
formed of GO terms (Table 2) related to muscle
development (including GO terms GO:0007517 and
GO:0007519), muscle contraction (including
GO:0006936, GO:0006941, and GO:0030731), and
muscle energy metabolism (including GO:0005977,
GO:0004368, and GO:0016600) and KEGG path-
ways (Table 3) related to energy (carbohydrate)
metabolism (including pathways 04910, 00010, and
00030) as well as VEGF and epithelial cell signal-
ing. It is notable that enrichment related to muscle
carbohydrate utilization and especially glycolysis is
present in several clusters. The PT specifically
upregulated five “insulin signaling” genes, both PT
and HRT upregulated six “glycolysis” or “insulin
signaling” genes, and finally 16 genes that showed
Fig. 3 Main functional
categories found to be
affected in postmenopausal
women. The number of
genes is presented in non-
redundant manner, i.e.,
“cytoplasm” includes a total
of 29 genes from which
nine are also included in the
“response to contraction”
and four in “energy metab-
olism” and therefore
excluded from the “other
cytoplasm-related” genes.
The same approach was
used in presenting the
number of genes in all
functional categories to
avoid overpresenting the
numbers. ↑ upregulation, ↓
downregulation
356 AGE (2010) 32:347–363uniform upregulation within all study groups had
“glycolysis”, “glycogen metabolism” or “insulin
signaling” annotation.
Other significantly and uniformly upregulated
genes, which also might have direct effects on
muscle functionality, were classified as “muscle
development” (eight genes) or “muscle contrac-
tion” (12 genes). Among these were two genes
encoding myosin heavy chain polypeptides (MYH1
and MYH8). To avoid confusion, the MYH1 gene,
which encodes for fast myosin heavy chain IIx
polypeptide, will be referred to as MYH IIx in this
report. Transcription of MYH IIx was substantially
upregulated in all study groups (FC: 2.40, 1.85 and
1.74 in the PT, HRT, and CO, respectively). The
relative proportion of MyHC IIx protein was also
increased in all study groups according to gel
electrophoresis analysis (FC: 1.9, 1.8 and 2.2 in the
PT, HRT, and CO, respectively; data not shown).
Transcription of MYH8, which encodes perinatal
myosin heavy chain polypeptide, was hardly detectable
as upregulated in the HRT group but substantially
more so in the PT and CO groups (FC: 1.84, 1.02, and
1.79 in the PT, HRT, and CO, respectively). The rest of
the genes in “muscle development”—related terms
were myostatin, FHL3, MAPK12, MYOD1, MEF2D,
MYF6, STK23,a n dMYLPF. These genes were
upregulated in the PT group by 25–54% and to a
lesser extent in the HRT and CO groups (3–21%),
except MYOD1, which had 30% upregulation in the
CO group, 14% upregulation in the HRT group, and
only 4% in the PT group (Supporting Table S1).
Of the genes downregulated in all groups (CL
#3), the largest common terms were related to
mitochondrial energy metabolism with 18 genes
contributing to the significance of three functional
categories (terms GO:0005739, 00190, and 00072
in Tables 2 and 3)a n do x i d a t i o n –reduction reactions
with 14 genes belonging to one or more of the
following categories: GO:0047115, GO:0016491,
GO:0004033, GO:0047026, GO:0047042,
GO:0032052, GO:0015721, and 00980 listed in
Tables 2 and 3. The next largest significant func-
tional category was “proteinaceous extracellular
matrix” with nine downregulated genes. Also GO/
KEGG categories: “regulation of muscle contrac-
tion”, “signaling through protein binding”, “lipid
metabolism,” and “regulation of cell cycle” were
affected.
Discussion
This study investigated global transcriptional changes
following power type of training and estrogen con-
taining hormonal replacement in skeletal muscle of
postmenopausal women. We found 665 differentially
expressed genes, which were assorted into eight non-
redundant clusters. PT appeared to have broader
effects on muscle metabolism, as seen in the number
of affected genes (510), while effects of HRT were
narrowed down to 54 changed genes. Moreover, the
“without treatment”—condition led to the discovery
of 161 genes with a significantly changed expression
pattern. Using enrichment analysis, we were able to
identify transcript groups, which were specific to PT,
specific to HRT, shared with PT and HRT, and finally
common to all studied, 50–57-year-old postmeno-
pausal women (Fig. 3).
Specific transcription responding to muscle
contraction
PT specifically affected transcription of nine genes
known to respond to muscle contraction. Among
these was STARS, which is considered to be an
important mediator linking changes in actin dynamics
and sarcomere structure with muscle gene expression
(Kuwahara et al. 2005). Recently, Lamon et al. (2009)
showed that resistance training stimulates the expres-
sion of STARS, which was associated with skeletal
muscle hypertrophy. Here we show, that also plyo-
metric power training, which improves muscle power
and composition (Sipilä et al. 2001; Taaffe et al.
2005) stimulates the expression of STARS.O u r
finding indicates that STARS expression is induced
by contraction per se and that the signaling through
STARS can be directed to different pathways either to
directly promote hypertrophy (Lamon et al. 2009), or
to improve muscle composition and neuromuscular
function (Taaffe et al. 2005). The components of such
pathways are most likely co-regulated and therefore
correlate closely with expression of STARS. In our
data, the change in the mRNA expression of STARS
did not correlate with change in any of the down-
stream genes investigated by Lamon et al. However,
we find high correlation with other genes. Therefore,
the ten most promising novel candidate genes (r=
0.54–0.68, p<0.00001) for STARS-related regulation
of muscle composition and function could be STIM,
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ETFA, AGL,a n dFHOD1.
PT and HRT have overlapping effects
on the carbohydrate metabolism-related transcription
Some mediators of the insulin signaling pathway were
upregulated solely by PT (five genes) and some by
both PT and HRT (six genes), suggesting overlapping
effects of these two interventions. PT specifically
upregulated the mRNA expression of AKT2 and
several other kinases as well as the expression of
GLUT4. AKT protein kinases have three isoforms from
which AKT2 is most important in modulating glucose
homeostasisbyregulatingGLUT4translocationintothe
plasma membrane in skeletal muscle (Gonzalez and
McGraw2009). Our result may indicate that the import
of glucose into muscle cells is increased in the PT
women assuming that the enhanced mRNA expression
will actually lead to a larger amount of GLUT4
proteins. Ten additional genes related to the insulin
signaling pathway were upregulated among all study
participants. These include OGT, which has been
recently identified as a suppressor of insulin signaling
and its hepatic overexpression causes insulin resistance
and dyslipidemia (Yang et al. 2008). The upregulation
of the OGT gene was most prominent within the CO
women (22%), and less obvious among the PT (12%)
and HRT (6%) women (Supporting Table S1). OGT
catalyzes the attachment of O-GlcNAc to proteins
providing post-translational modification comparable
and often competitive to phosphorylation. The rate of
O-GlcNAcetylation is highly dependent on the avail-
ability of intracellular glucose, from which 2–5% is
converted into UDP-GlcNAc, the donor substrate for
GlcNAcetylation (Marshall et al. 1991). Therefore,
OGT functions as an energy sensor, capable of
regulating signal transduction, transcription, and pro-
teosomal degradation (Wells et al. 2003;C o p e l a n de t
al. 2008). In addition, many genes directly related to
glycolysis were upregulated either in both PTand HRT
groups (three genes) or in all three study groups (seven
genes). The mRNA expressions of all major enzymes
(PGM1, PFKM, FBP2, ALDOA,a n dTPI1)n e e d e df o r
conversions of glucose to C3-carbohydrates were
upregulated at the mRNA level. Also the mRNA
expression of PKM2, which is a glycolytic enzyme that
catalyzes the transfer of a phosphoryl group from
phosphoenolpyruvate to ADP thus generating ATP
(Ikeda and Noguchi 1998), was upregulated in the PT
and HRT groups. Taken together, it seems that the
tendency to increase transcription related to carbohy-
drate metabolism after menopause is further enhanced
by PT and HRT and finally manifests as better muscle
performance. It is also possible that after menopause,
the excess of sugar metabolites starts to accumulate,
which produces a need to enhance both insulin
signaling and glycolysis. Further studies are needed
to verify if this strain observed here at mRNA level is
due to an increment in energy need per se, due to
truncation in energy production or due to inefficiency
in energy utilization after menopause and whether the
increments at mRNA level will lead to actual incre-
ments of corresponding proteins/enzymes.
Parallel activation of calcium signaling pathway
by PT and HRT
Yet another candidate pathway for improving muscle
performance is the calcium signaling pathway. Myo-
plasmic calcium (Ca
2+) is a well-known secondary
messenger involved in excitation–contraction coupling
(Melzer et al. 1995) and is believed to be involved in
an array of cellular functions including carbohydrate
metabolism, gene transcription, protein synthesis, and
mitochondrial biogenesis, further increasing the diver-
sity of the pathway (Hook and Means 2001;W ue ta l .
2002; Wright 2007; Rose and Richter 2008; Illario et
al. 2009;R o s ee ta l .2009). In our study, five members
of the calcium signaling pathway, namely two calm-
odulins: CALM1 and CALM3, and three calmodulin
and/or Ca
2+-activated kinases: PHKG1, CaMK2A,a n d
CaMK2B, showed consistent transcriptional activation.
Training increased expression of these genes by 20–
30%, and the use of HRT by 0–15%, while the same
genes were slightly downregulated in the CO group
(2–13%, Supporting Table S1). It is well established
that, contraction-induced elevation in Ca
2+ concentra-
tion leads to rapid activation of CALMs, which in turn
activate multifunctional CaMK kinases among other
downstream targets (Walsh 1983). Our results suggest
that the transcription of CaMK2, the most abundant
CaMK in skeletal muscle, is regulated by physical
exercise and that long-term PT leads to elevated
basal mRNA levels. This is in line with protein level
studies in which the activity of CaMK2 has been
s h o w nt ob er a p i d l yi n d u c e db ye x e r c i s ei na n
intensity dependent manner (Rose et al. 2005). It is
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increases the mRNA and protein expression of
GLUT4. The mechanism for an exercise-induced
increment is not entirely clear, but it has been
suggested that it may go through an increase in
intracellular Ca
2+ content, which activates CaMK
and calcineurin, which in turn activates specific
transcription factors including MEF2 (Holmes and
Dohm 2004). Our results support this hypothesis and
suggest that PT also directly affects the transcription
of CaMK, but not that of calcineurin, whose
transcription was not induced in our study. The
mechanism by which HRT is able to resist decre-
ments in CALM1, CALM3, PHKG1, CaMK2A,a n d
CaMK2B transcription, which was seen among the
CO women, is not known.
HRT aids in maintaining muscle mitochondrial
function via transcriptional regulation
One important and interesting aspect of aging-related
phenomena discovered in previous microarray studies
is the enhanced negative transcriptional regulation of
oxidative phosphorylation and other mitochondrial
functions with advancing age (Welle et al. 2003;
Welle et al. 2004; Zahn et al. 2006; Melov et al. 2007;
Welle et al. 2008). This downregulation was also
observed in our study with early postmenopausal,
middle-aged women. In our data, 29 genes with GO
annotation “mitochondrion” or related to “oxidore-
ductase activity” were downregulated in all study
groups within the 1-year interval. However, down-
regulation of “mitochondrion” genes was only
minimal among the HRT women being 0–13% for
most of the genes and 16–23% for nine genes
related to oxidation events (Supporting Table S1).
Much more severe downregulation was observed in
the PT (5–55%) and CO (3–46%) groups. Moreover,
there was specific upregulation of another set of 12
“mitochondrion”—genes within the HRT women
(Fig. 3). Even though the upregulation of these
genes was modest (0–13%) among the HRT women,
the same genes were downregulated substantially
more among the PT (12–53%) and CO (2–33%)
women (Supporting Table S1). This data indicates
that HRT may be beneficial for maintaining proper
functionality of mitochondria, which seems to start
accumulatingnegativetranscriptionalregulationalready
in the early postmenopausal years. Furthermore,
contrary to strength-based resistance (Melov et al.
2007) and endurance training (Mahoney et al. 2005),
the plyometric power training used in the current
study was not effective in resisting negative tran-
scriptional regulation of mitochondria. We also had
some muscle samples (n=46) taken 6 months after
the initiation of the Ex/HRT intervention, from
which we determined the amount of mitochondrial
DNA relative to genomic DNA in order to count the
number of mitochondria. However, we did not
observe differences in the number of mitochondria
between the samples of PT, HRT, and CO women
(data not shown), which indicates that the regulation
is on functionality rather than the number of
mitochondria.
Transcriptional regulation of myogenesis and muscle
contraction-related genes in all study groups
We found that several functional categories directly
related to myogenesis, muscle structure, and function
were affected during the first years postmenopause
(Fig. 3). Eight “muscle development”—genes were
upregulated within all study groups. For example,
from the four members of MYOD1-family of myo-
genic regulatory factors (MYOD1, myogenin, MYF5,
and MYF6), both MYOD1 and MYF6 were found to
be upregulated within all study groups. These
transcription factors have both specific and redundant
functions during muscle development, and their
activation is required for satellite cell differentiation
during myogenesis and muscle regeneration
(Yablonka-Reuveni and Rivera 1994; Yablonka-
Reuveni et al. 1999). Also, the MEF2 transcription
factor family includes four genes, which have
sequential expression patterns during muscle devel-
opment. The MEF2 gene, which we found to be
activated among all study participants, was MEF2D,
whose binding to the promoter of MYOD1 is required
for increase and maintenance of MYOD1 expression
during differentiation into myotubes (L’honore et al.
2007). Taken together, it seems that transcriptional
regulation of myogenesis and muscle regeneration is
activated in the early postmenopausal women.
Furthermore, functional categories “regulation of
contraction,”“ muscle contraction,” and “extracellular
matrix” were enriched among all study groups
(including 11 upregulated and 14 downregulated
genes). In addition, PT specifically affected another
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contraction (nine upregulated genes). In studies by
Welle and co-workers (Welle et al. 2003; Welle et al.
2004), MYH8 encoding the perinatal myosin heavy
chain, was found to be upregulated with aging.
Similarly, we found that MYH8 was upregulated
within all study groups albeit the upregulation was
barely visible within the HRT group (2%) but much
more pronounced in the PT (84%) and CO (79%)
groups (Supporting Table S1). Expression of MYH8
dominates the early skeletal muscle development, and
it is re-expressed in regenerating muscles (d’Albis et
al. 1988; Weiss et al. 1999). Regeneration requires the
activation of quiescent satellite cells to proliferate and
differentiate into myoblasts, which eventually fuse
with existing muscle fibers to repair damage or to
help fibers to cope with physiological demands. Even
though the expression level of perinatal MYH8 was
low compared to the adult MYH genes, MYH I, MYH
IIa, and MYH IIx, the observed substantial increment
in the expression in the PT and CO groups may
indicate increased demand for myofiber regeneration.
Furthermore, this demand appeared to be absent
among women using HRT possibly because they
were the only group able to maintain and even
increase their muscle mass.
Strengths and caveats of the current study
Most of the expression array studies investigating
the effects of aging (Welle et al. 2003; Welle et al.
2004;G i r e s ie ta l .2005;Z a h ne ta l .2006)a r ec r o s s -
sectional studies and compare old (65–80 years old)
to younger (19–30 years old) participants neglecting
the middle-aged population. Furthermore, only one
study has included women (Welle et al. 2004).
Therefore, our study with early postmenopausal 50–
57-year-old women extends the work undertaken in
previous studies. We studied the transcriptional changes
using the age group, which according to earlier studies
(Kallman et al. 1990; Phillips et al. 1993;S a m s o ne ta l .
2000) is just beginning to accumulate deteriorations in
their muscle function. This age range is optimal for
detecting the first alterations in transcriptome even
before they are fully translated to the phenotype. The
relatively small sample size may, however, affect the
results. On the other hand, the long duration of our
study enables us to examine true adaptation to treat-
ments both at the phenotype and transcriptome level.
For skeletal muscle tissue, 1 year is a rather long
follow-up since muscle is highly adaptive to changes
in, e.g., loading conditions. Furthermore, the RCT
design with repeated measures analysis and using a
single HRT preparation strengthens our study by
eliminating physiological and genetic differences in
responses to training or HRT and, therefore, enables
the detection of true intra-individual responses.
To date, many studies have used quantitative PCR
(qPCR) to confirm microarray results. For example, in
16 microarray studies using human muscle tissue as a
source for RNA (Roth et al. 2002;R o m ee ta l .2003;
Welle et al. 2003;Z a m b o ne ta l .2003; Welle et al.
2004; Wittwer et al. 2004; Mahoney et al. 2005; Teran-
Garcia et al. 2005; Schmutz et al. 2006;C h e ne ta l .
2007; Melov et al. 2007; Pöllänen et al. 2007; Sjogren
et al. 2007; Thalacker-Mercer et al. 2007; Welle et al.
2008;S t e p t oe ta l .2009) and indicating the use of
qPCR as validation method, 2–9 genes have been re-
analyzed using either the same or different RNA pool.
In ten cases, the microarray results were totally
confirmed, and in six cases, there were 1–2f a i l u r e s
(out of nine, eight, seven, six, and five genes studied).
Importantly, all failures have been on genes with the
low level of expression. This also holds true for the
array platform used in the current paper as demon-
strated by Melov et al (2007) and Pöllänen et al (2007).
Building on this literature, the quality and reproduc-
ibility of microarray experiments are nowadays well
established, and additional validation with qPCR seems
to be unnecessary, at least as far as the lowest
expression levels are not considered. A more valuable
extension would come from analyzing, e.g., protein
samples, which we unfortunately were unable to do for
other than the MyHC proteins, due to lack of samples.
In addition to the molecular level data, we have
conducted comprehensive muscle phenotype analyses
including tests for muscle power, strength, perfor-
mance, composition, and mass (Sipilä et al. 2001;
Taaffe et al. 2005). The results obtained showed the
effectiveness of the PT and HRT on these phenotypes,
which we believe is due to the observed changes in
muscle transcriptome.
Conclusions
This study showed that several functional gene
categories, which may directly affect the preservation
360 AGE (2010) 32:347–363of neuromuscular performance after menopause, are
already altered within the first years of the
postmenopausal period and that some of these are
modulated by 12-month power training and/or
hormonal replacement. The newly observed tran-
scriptional changes partially explain phenotypic
improvements after PT or HRT (Sipilä et al. 2001;
Taaffe et al. 2005) and provide novel insights for
further studies. For example, contraction-induced gene
regulation via STARS, transcriptional activation of
ALDOA and other glycolysis enzymes, regulation of
signal transduction via OGT and insulin, and main-
taining functionality of mitochondria as well as
regulation of adult myogenesis and myofiber regener-
ation are all important but not thoroughly studied
mechanisms involved in the regulation of muscle
power, performance and quality after menopause.
Taken together, our main findings indicate that PT
and/or HRT may function through improving energy
metabolism and response to contraction as well as by
preserving functionality of mitochondria in skeletal
muscle of postmenopausal women.
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